Sexually transmitted diseases and HIV co-infection among adult male patients in the 2022 monkeypox outbreak: a systematic review and meta-analysis.

Autor: Abu-Hammad O; School of Dentistry, University of Jordan, Amman, Jordan., Arabiat D; School of Nursing, University of Jordan, Amman, Jordan., Althagafi N; College of Dentistry, Taibah University, Al Madinah Al Munawara, Saudi Arabia., Eshky R; College of Dentistry, Taibah University, Al Madinah Al Munawara, Saudi Arabia., Abu-Hammad A; School of Medicine, University of Jordan, Amman, Jordan., Jaber AR; School of Medicine, University of Jordan, Amman, Jordan., Jaber AR; School of Medicine, University of Jordan, Amman, Jordan., Dar-Odeh N; School of Dentistry, University of Jordan, Amman, Jordan.; College of Dentistry, Taibah University, Al Madinah Al Munawara, Saudi Arabia.
Jazyk: angličtina
Zdroj: Dermatology reports [Dermatol Reports] 2024 Feb 06; Vol. 16 (2), pp. 9860. Date of Electronic Publication: 2024 Feb 06 (Print Publication: 2024).
DOI: 10.4081/dr.2024.9860
Abstrakt: This meta-analysis estimates sexually transmitted disease (STI) and HIV rates in male monkeypox patients during the 2022 outbreak. The study examines contextual factors that increase monkeypox risk. A systematic review of PubMed/Medline, Scopus, and Google Scholar was conducted to find observational studies on monkeypox patients' demographics and medical characteristics from the 2022 outbreak. This review's meta-analysis followed the System for the Unified Management, Assessment, and Review of Information - Joanna Briggs Institute (SUMARI JBI) guidelines. All HIV and STI prevalence data for male monkeypox patients was exported into the SUMARI JBI. For point prevalence of HIV and STIs, we used the Freeman-Tukey-type arcsine square root transformation to stabilize raw proportion variances. A fixed-effects model weighted and pooled all estimates by inverse variance. We then used a random model to account for sampling variation and reported fixed-effect model effect size heterogeneity across studies. Study heterogeneity was measured using the I 2 test statistic and P-values. I 2 test results were interpreted as low (25%), moderate (50%), and high (75%). Six Spanish and English studies qualified. These studies included 541 male monkeypox patients, 214 of whom had HIV and 255 with other STIs. HIV prevalence was estimated at 40% (95% CI = 0.31%, 0.50%; ᵡ2=15) and STIs at 43% (95% CI = 25%, 61%; ᵡ2=118). Overall, analyses showed moderate to high heterogeneity. Four in ten male monkeypox patients in 2022 had HIV or other STIs. To prevent HIV and other STIs, public health measures should target male and female monkeypox patients.
Competing Interests: Conflict of interest: the authors declare no potential conflict of interest.
(Copyright © 2024, the Author(s).)
Databáze: MEDLINE
Externí odkaz: